Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotinurad vs Febuxostat in Chinese Gout Patients
NCT05007392Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dotinurad in gout, sponsored by Eisai Co., Ltd.. Started Dec 2021; status: completed.
02
Drugs
dotinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT05007392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007392.